Material Agreements

CNL Strategic Residential Credit, Inc. entered into Loan Agreement with Valley National Bank valued at $15,000,000.00 (effective 2025-12-31).

“On December 31, 2025, CNL Strategic Residential Credit, Inc. (referred to herein as “we”, “us”, “our” or the “Company”) and Valley National Bank, a Tennessee banking corporation, (referred to as “Valley National Bank”) entered into a Loan and Security Agreement (the “Loan Agreement”) for a revolving line of credit (the “Line of Credit”) for up to Fifteen Million Dollars ($15,000,000.00)”

AMERISERV FINANCIAL INC /PA/ amended Amended and Restated Consulting Agreement with SB Value Partners, L.P. (effective 2026-01-06).

“the Company entered into an Amended and Restated Consulting Agreement (the “ Agreement ”) with the Advisor on January 6, 2026 pursuant to which, among other things, the Company desires to expand and supplement the nature and scope of the consulting services to be provided by the Advisor (the “ Phase II Consulting Services ”).”

Ventas, Inc. amended Amendment with the lenders identified therein and Bank of America, N.A., as administrative agent (effective 2026-01-07).

“On January 7, 2026, Ventas Realty, Limited Partnership (the “Borrower”), a wholly owned subsidiary of Ventas, Inc. (the “Company”), and the Company, as guarantor, entered into an amendment to the Credit Agreement (as defined below) (the “Amendment”) with the lenders identified therein and Bank of America, N.A., as administrative agent, pursuant to which that certain Credit and Guaranty Agreement (the “Credit Agreement”), dated as of June 27, 2022, among the Borrower, the Company, the lenders identified therein and Bank of America, N.A., as administrative agent, was amended to, in addition to certain technical amendments, (i) increase the term loans under the Company’s existing unsecured term loan facility (the “Term Loan Facility”) from $500 million to $700 million and (ii) establish a new unsecured delayed draw term loan facility in a principal amount of $550 million (the “Delayed Draw Term Loan Facility”, and together with the Term Loan Facility, the “Facilities”).”

ALASKA AIR GROUP, INC. entered into supplemental agreement with The Boeing Company (effective 2025-12-31).

“On December 31, 2025 Alaska Airlines, Inc. (Alaska) entered into a supplemental agreement with The Boeing Company, pursuant to which Alaska finalized an order to purchase 53 incremental 737-10 aircraft scheduled for delivery between 2032 and 2035, and exercised 52 737-10 option aircraft scheduled for delivery between 2028 and 2032.”

BION ENVIRONMENTAL TECHNOLOGIES INC amended Secured Convertible Promissory Notes with holders of Bion’s Secured Convertible Promissory Notes and holders of Bion’s May 2024 Convertible Promissory Notes (effective 2025-12-31).

“All holders of Bion’s Secured Convertible Promissory Notes, along with all holders of Bion’s May 2024 Convertible Promissory Notes, both Notes with a maturity date of December 31, 2025, have agreed to extend their maturity date, under the same terms until June 30, 2026.”

Arena Group Holdings, Inc. amended Renew Amendment with Renew Group Private Limited valued at $13.0 million payment (effective 2025-12-31).

“On December 31, 2025, the Company entered into an amendment (the “Renew Amendment”) to its Third Amended and Restated Note Purchase Agreement dated December 15, 2022, as amended on August 14, 2023, December 1, 2023 and July 12, 2024, with Renew Group Private Limited (“Renew”), as lender (the “Renew Loan”).”

Arena Group Holdings, Inc. amended Simplify Amendment with Simplify Inventions, LLC valued at up to $25 million (effective 2025-12-31).

“On December 31, 2025, The Arena Group Holdings, Inc. (the “Company”) entered into an amendment (the “Simplify Amendment”) to its loan agreement dated March 13, 2024, as amended on August 19, 2024, with Simplify Inventions, LLC (“Simplify”) as lender (the “Simplify Loan”).”

TANGER PROPERTIES LTD PARTNERSHIP /NC/ amended Liquidity Credit Agreement with Bank of America, N.A., as administrative agent (effective 2026-01-06).

“In addition, the Operating Partnership closed on amendments to each of (i) the Fifth Amended and Restated Credit Agreement dated April 12, 2024 (as amended and/or restated, the "Revolving Credit Agreement") among the Operating Partnership, Bank of America, N.A., as administrative agent, and the lenders party thereto, and (ii) the Fifth Amended and Restated Liquidity Credit Agreement, dated April 12, 2024 (as amended and/or restated, the "Liquidity Credit Agreement") among the Operating Partnership, Bank of America, N.A., as administrative agent, and the lenders party thereto, such amendments in each case removing the 10 basis point SOFR credit adjustment spread and making certain conforming changes from the 2030 Term Loan Agreement and the 2033 Term Loan Agreement.”

TANGER PROPERTIES LTD PARTNERSHIP /NC/ amended Revolving Credit Agreement with Bank of America, N.A., as administrative agent (effective 2026-01-06).

“In addition, the Operating Partnership closed on amendments to each of (i) the Fifth Amended and Restated Credit Agreement dated April 12, 2024 (as amended and/or restated, the "Revolving Credit Agreement") among the Operating Partnership, Bank of America, N.A., as administrative agent, and the lenders party thereto, and (ii) the Fifth Amended and Restated Liquidity Credit Agreement, dated April 12, 2024 (as amended and/or restated, the "Liquidity Credit Agreement") among the Operating Partnership, Bank of America, N.A., as administrative agent, and the lenders party thereto, such amendments in each case removing the 10 basis point SOFR credit adjustment spread and making certain conforming changes from the 2030 Term Loan Agreement and the 2033 Term Loan Agreement.”

TANGER PROPERTIES LTD PARTNERSHIP /NC/ entered into 2033 Term Loan Agreement with Toronto Dominion (Texas) LLC, as administrative agent valued at $200 million (effective 2026-01-06).

“Additionally, the Operating Partnership closed on a Term Loan Agreement (the "2033 Term Loan Agreement") among the Operating Partnership, Toronto Dominion (Texas) LLC, as administrative agent, and the lenders party thereto, for a new unsecured term loan (including a delayed draw feature) with a maximum amount available to be borrowed of $200 million and a maturity date of January 6, 2033.”

TANGER PROPERTIES LTD PARTNERSHIP /NC/ amended 2030 Term Loan Agreement with Wells Fargo Bank, National Association, as administrative agent valued at from $325 million to $350 million (effective 2026-01-06).

“On January 6, 2026, Tanger Properties Limited Partnership (the “Operating Partnership"), a majority owned subsidiary of Tanger Inc. (the “Company”), closed on a Fourth Amended and Restated Term Loan Agreement (the "2030 Term Loan Agreement") among the Operating Partnership, Wells Fargo Bank, National Association, as administrative agent, and the lenders party thereto.”

PLUG POWER INC entered into Release Event License Agreement with Walmart Inc. valued at a one-time initial license fee (effective 2025-12-30).

“On December 30, 2025 (the “Effective Date”), Plug Power Inc. (the “Company”) entered into a Release Event License Agreement (the “License Agreement”) with Walmart Inc. (“Walmart”)”

Dror Ortho-Design, Inc. entered into Securities Purchase Agreement with each of the purchasers signatory thereto valued at $250,000 (effective 2025-12-30).

“On December 30, 2025, Dror Ortho-Design, Inc. (the “Company”), a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers signatory thereto (each, a “Purchaser” and, collectively the “Purchasers”).”

T-Mobile US, Inc. entered into Second Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders, swingline lenders and L/C issuers party thereto valued at $10.0 billion (effective 2026-01-05).

“entered into a Second Amended and Restated Credit Agreement (the “Credit Agreement”) by and among T-Mobile USA, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders, swingline lenders and L/C issuers party thereto.”

T-Mobile US, Inc. terminated Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders, swingline lenders and L/C issuers party thereto.

“(“Parent”), entered into a Second Amended and Restated Credit Agreement (the “Credit Agreement”) by and among T-Mobile USA, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders, swingline lenders and L/C issuers party thereto.”

IGC Pharma, Inc. entered into 2025 Subscription Agreement with certain investors valued at approximately $234 thousand (effective 2026-01-05).

“entered into a Subscription Agreement (the “2025 Subscription Agreement”) with certain investors named therein (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “Offering”), an aggregate of 779,997 shares of the Company’s common stock”

eHealth, Inc. entered into New Revolving Credit Agreement with CCP Agency, LLC valued at $125.0 million (effective 2025-12-31).

“On December 31, 2025 (the “Closing Date”), eHealthInsurance Services, Inc. (the “Borrower”), a wholly owned indirect subsidiary of eHealth, Inc. (the “Company”), entered into a credit agreement with CCP Agency, LLC, as agent (the “Agent"), and the lenders party thereto (the “New Revolving Credit Agreement”) providing for a new asset-based revolving credit facility (the “New Revolving Credit Facility”) with aggregate commitments of up to $125.0 million”

CareView Communications Inc amended Thirteenth Amendment to Credit Agreement with PDL Investment Holdings, LLC (effective 2025-12-31).

“As of December 31, 2025, the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Thirteenth Amendment to CA (the “Thirteenth Amendment to Credit Agreement”), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to March 31, 2026.”

Sunrun Inc. amended Amendment No. 4 with KeyBank National Association, as administrative agent, and the other parties thereto valued at approximately $321,394,000 (effective 2025-12-31).

“On December 31, 2025, Sunrun Inc. (the “Company”) entered into Amendment No. 4 (“Amendment No. 4”) to that certain Credit Agreement, dated as of January 24, 2022 (as amended by Amendment No. 4, the “Credit Agreement”), by and among the Company, KeyBank National Association, as administrative agent, and the other parties thereto, to, among other things, (a) extend the stated maturity date from March 1, 2027 to March 1, 2028, (b) reduce the commitments to approximately $321,394,000”

KALA BIO, Inc. entered into Delaware IR Settlement with Delaware IR LLC valued at Issued 1,100,000 shares of common stock to settle $600,000 owed (effective 2025-12-30).

“Under the settlement agreement, the Company agreed to issue 1,100,000 shares of Common Stock to settle the outstanding $600,000 amount owed under the consulting agreement, with a make-whole mechanic tied to ultimate net sale proceeds from the future sales of the 1,100,000 shares of Common Stock (the “Delaware IR Settlement”).”

KALA BIO, Inc. entered into Delaware IR Consulting Agreement with Delaware IR LLC valued at Marketing and advertising services for six months for $600,000 (effective 2025-12-30).

“On December 30, 2025, the Company also entered into a consulting agreement and a settlement agreement with Delaware IR LLC (“Delaware IR”). Under the consulting agreement, Delaware IR agreed to provide marketing and advertising services for a six-month term for $600,000.”

KALA BIO, Inc. entered into LifeSci Settlement with LifeSci Capital LLC valued at Issued 2,200,000 shares of common stock (effective 2025-12-30).

“On December 30, 2025, the Company also entered into a settlement agreement with LifeSci Capital LLC (“LifeSci”) under which the Company agreed to issue 2,200,000 shares of Common Stock to settle certain payment obligations for financial advisory services (the “LifeSci Settlement”).”

KALA BIO, Inc. entered into Baker Voting Agreement with Baker Bros. Advisors LP valued at Granted irrevocable proxy for six months (effective 2025-12-30).

“In connection with the Baker Settlement, the Company and Baker Bros. also entered into a voting agreement (the “Baker Voting Agreement”) under which Baker Bros. granted an irrevocable proxy in favor of the Company to vote the settlement shares and other specified shares in line with the Company’s board of director’s recommendations for a period of six months.”

KALA BIO, Inc. entered into Baker Settlement with Baker Bros. Advisors LP valued at Issued 900,000 shares of common stock (effective 2025-12-30).

“On December 30, 2025, KALA BIO, Inc. (the “Company”) entered into a settlement agreement with Baker Bros. Advisors LP (“Baker Bros.”) under which the Company agreed to issue 900,000 shares of its common stock, par value $0.001 per share (“Common Stock”) to resolve certain claims relating to participation rights under prior financing arrangements (the “Baker Settlement”).”

Skyward Specialty Insurance Group, Inc. amended First Amendment with Barclays Bank PLC (effective 2025-12-30).

“On December 30, 2025, the Company entered into the First Amendment (the “Amendment”) to the Credit Agreement, dated November 13, 2025 (the “Existing Credit Agreement”), by and among the Company, the guarantors party thereto, the lenders party thereto and Barclays Bank PLC, as administrative agent.”

Skyward Specialty Insurance Group, Inc. entered into Guaranty Agreement with subsidiary guarantors (effective 2025-12-30).

“In connection with the Credit Agreement, on December 30, 2025, the Company and the subsidiary guarantors party thereto, entered into a Guaranty Agreement (the “Guaranty Agreement”), pursuant to which the Company’s obligations under the Facility are guaranteed by the Company and its existing wholly-owned subsidiaries and subsequently acquired or organized subsidiaries”

Skyward Specialty Insurance Group, Inc. entered into Term Loan Credit Agreement with Barclays Bank PLC, Truist Securities, Inc., Citizens Bank, N.A., Texas Capital Bank valued at $300.0 million (effective 2025-12-30).

“On December 30, 2025, the Company entered into a Term Loan Credit Agreement (the “Facility”) by and among the Company, as Borrower, the lenders from time to time parties thereto (each a “Lender” and collectively, the “Lenders”), Barclays Bank PLC, as Administrative Agent (the “Agent”), and the Agent, Truist Securities, Inc., Citizens Bank, N.A. and Texas Capital Bank as joint lead arrangers, joint book runners and co-syndication agents for the Tranche B Term Facility.”

SolarMax Technology, Inc. entered into a supply with Navboot Holdco, LLC valued at approximately $258.1 million (effective 2025-12-31).

“Pursuant to an EPC agreement with Navboot Holdco, LLC, a Delaware limited liability company (“Navboot”), SREP is to develop a BESS facility in Corpus Christi, Texas. The contract is expected to generate revenues of approximately $258.1 million.”

SolarMax Technology, Inc. entered into a supply with Yabucoa BESS LLC valued at approximately $35.9 million (effective 2025-12-31).

“Pursuant to an EPC agreement with Yabucoa BESS LLC, a Texas limited liability company (“Yabucoa”), SREP is to develop a BESS facility in Humacao Municipality, Puerto Rico. The contract is expected to generate revenues of approximately $35.9 million.”

SolarMax Technology, Inc. entered into a supply with Naguabo BESS LLC valued at approximately $122.3 million (effective 2025-12-31).

“Pursuant to an EPC agreement with Naguabo BESS LLC, a Texas limited liability company (“Naguabo”), SREP is to develop a BESS facility in Ceiba Municipality, Puerto Rico. The contract is expected to generate revenues of approximately $122.3 million.”

Harvard Apparatus Regenerative Technology, Inc. entered into Purchase Agreement with certain investors valued at aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 m (effective 2025-12-30).

“Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”), each effective as of December 30, 2025, with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 million and a purchase price per share of $1.70 (the “Private Placement”).”

BayFirst Financial Corp. amended Amendment with the holders of the Company’s $6.0 million of 4.5% Fixed to Floating Subordinated Notes Due June 30, 2031 valued at $6.0 million (effective 2025-12-26).

“On December 29, 2025, BayFirst Financial Corp. (the “Company”) and the holders of the Company’s $6.0 million of 4.5% Fixed to Floating Subordinated Notes Due June 30, 2031 (the “Notes”) entered into an Amendment to the Notes (the “Amendment”), effective as of December 26, 2025.”

Cyclerion Therapeutics, Inc. entered into Collaboration and Option Agreement with Medsteer, SAS valued at up to $3.7 million (effective 2026-01-03).

“On January 3, 2026, Cyclerion Therapeutics, Inc. (the “Company”) and the Medsteer, SAS (“Medsteer”) entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer”

Tradeweb Markets Inc. amended Amendments to Master Data Agreement with Refinitiv US LLC and Refinitiv US Organization LLC (LSEG Parties) valued at fixed license fees or fees based on percentage of revenue (effective 2025-11-01).

“On December 31, 2025, Tradeweb Markets LLC (“Tradeweb Markets”), a wholly owned subsidiary of Tradeweb Markets Inc. (the “Company”), entered into a series of amendments effective as of November 1, 2025 (the “Amendments”) with Refinitiv US LLC and Refinitiv US Organization LLC (together, the “LSEG Parties”) to the master data license agreement, effective as of November 1, 2023, among Tradeweb Markets and the LSEG Parties (the “Master Data Agreement”).”

Instil Bio, Inc. terminated License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (effective 2026-01-05).

“Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License and Collaboration Agreement dated August 1, 2024 between ImmuneOnco and Axion”

Blue Owl Credit Income Corp. entered into Secured Credit Facility with Société Générale, as administrative agent and swingline lender, State Street Bank and Trust Company, as collateral agent, collateral administrator, custodian and document custodian, and the lenders party thereto valued at $750 million (effective 2025-12-31).

“On December 31, 2025 (the “Closing Date”), Core Income Funding X LLC (“Core Income Funding X”), a Delaware limited liability company and a newly formed subsidiary of Blue Owl Credit Income Corp., a Maryland corporation (the “Company” or “us”) entered into a Revolving Credit and Security Agreement (the “Secured Credit Facility”), with Core Income Funding X, as borrower, Société Générale, as administrative agent and swingline lender, State Street Bank and Trust Company, as collateral agent, collateral administrator, custodian and document custodian, and the lenders party thereto.”

Estrella Immunopharma, Inc. entered into Registration Rights Agreement with the Investor (effective 2026-01-05).

“In connection with the Private Placement, the Company and the Investor entered into a registration rights agreement, dated January 5, 2026 (the “Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement (the “Resale Registration Statement”), providing for the resale of the shares of Common Stock issued and issuable upon exercise of the PIPE Common Warrants within thirty (30) days of the closing of the Offering, to have such registration statement declared effective within sixty (60) days of the closing date (or ninety (90) days of the closing date if the SEC conducts a full review of a Resale Registration Statement), and to maintain the effectiveness of such registration statement until the earlier of (i) the date on which all such securities have been sold thereunder or pursuant to Rule 144, or (ii) the date on which such securities are eligible for resale without the need for registration under the Securities Act.”

Estrella Immunopharma, Inc. entered into Placement Agent Agreement with Aegis Capital Corp. (effective 2026-01-05).

“In connection with the Offerings, the Company also entered into a placement agent agreement, dated January 5, 2026 (the “Placement Agent Agreement”), with Aegis Capital Corp. (the “Placement Agent”), pursuant to which the Company paid the Placement Agent a cash fee equal to 6.0% of the aggregate gross proceeds of the Offerings and reimbursed the Placement Agent for certain expenses and legal fees.”

Estrella Immunopharma, Inc. entered into Securities Purchase Agreement with a healthcare-focused institutional investor valued at approximately $8.0 million (effective 2026-01-05).

“On January 5, 2026, Estrella Immunopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with a healthcare-focused institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor (a) in a registered direct offering (the “Registered Direct Offering”) (i) 4,063,290 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,000,000 shares of Common Stock for $0.00001 per share; and (b) in a concurrent private placement (the “Private Placement,” and together with the Registered Direct Offering, the “Offerings”), common stock purchase warrants (the “PIPE Common Warrants”), exercisable for up to an aggregate of 7,594,935 shares of Common Stock for $1.39 per share, subject to customary anti-dilution adjustments for stock splits, reclassifications and recapitalizations of the Co”

Day One Biopharmaceuticals, Inc. entered into CVR Agreement with Rights Agent (effective 2026-01-06).

“on January 6, 2026, the Parent and the Rights Agent entered into the CVR Agreement governing the terms of the CVRs issued pursuant to the Offer and the Merger”

Aspire Biopharma Holdings, Inc. entered into Exchange Agreements with certain holders of the Company’s debt valued at approximately $1.75 million (effective 2026-01-01).

“On January 1, 2026, the Company entered into Exchange Agreements (the “Exchange Agreements”) with certain holders of the Company’s debt (the “Holders”) to exchange approximately $1.75 million in debt for shares (the “Exchange Shares’) of the Company’s common stock (the “Exchange”).”

OneStream, Inc. entered into Agreement and Plan of Merger with Onward AcquireCo, Inc., Onward Merger Sub 2, LLC, Onward Merger Sub, Inc. valued at $24.00 (effective 2026-01-06).

“On January 6, 2026, OneStream, Inc. (“OneStream”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with OneStream Software LLC (“OneStream LLC” and, together with OneStream, the “OneStream Parties”), Onward AcquireCo, Inc. (“Parent”), Onward Merger Sub 2, LLC (“Merger Sub I”) and Onward Merger Sub, Inc. (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”).”

Mobileye Global Inc. entered into Share Purchase Agreement with Mentee Robotics Ltd. valued at $900,000,000 (effective 2026-01-05).

“On January 5, 2026, Mobileye Global Inc. (the “Corporation”), a Delaware corporation, and Mobileye Vision Technologies Ltd. (“MEIL”), a company organized under the laws of the State of Israel and a subsidiary of the Corporation, entered into a share purchase agreement (the “Share Purchase Agreement”) to acquire 100% of the issued and outstanding stock of Mentee Robotics Ltd.”

RenX Enterprises Corp. entered into Notes with Commercial Credit Group valued at approximately $2.54 million (effective 2025-12-30).

“Effective December 30, 2025, Resource Group LLC (“Resource Group”), a wholly owned subsidiary of RenX Enterprises Corp. (the “Company”), entered into a Negotiable Promissory Note and Security Agreement in the principal amount of $1,507,658 (the “First Note”) and Negotiable Promissory Note and Security Agreement in the principal amount of $1,047,528 (the “Second Note”; and together with the First Note, the “Notes”) with Commercial Credit Group (the “Lender”) to finance the purchase of a Komptech Crambo shredder and a Diamond Z horizontal grinder for approximately $2.54 million with a 30% down payment of approximately $700,000 that had previously been deployed under a rental arrangement.”

Marblegate Capital Corp entered into Loan and Security Agreement with Auxilior Capital Partners, Inc. valued at approximately $17.2 million (effective 2025-12-31).

“On December 31, 2025, certain wholly owned subsidiaries (the “ Mini-Fleets ”) of DePalma Acquisition II LLC (“ DPA 2 ”) entered into a Loan and Security Agreement (the “ Vehicle Loan Agreement ”) with Auxilior Capital Partners, Inc. (“ Auxilior ”), which provides for loans in the aggregate amount of approximately $17.2 million to finance certain fleets of taxicab vehicles.”

Marblegate Capital Corp entered into Membership Interest Purchase Agreement with TML Holding, Inc. and DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Frankfurt Am Main, New York Branch valued at approximately $15.8 million (effective 2025-12-30).

“On December 30, 2025, MCC also entered into a Membership Interest Purchase Agreement (the “ MIPA ”) with TML Holding, Inc. (the “ Seller ”) and DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Frankfurt Am Main, New York Branch, pursuant to which MCC purchased 100% of the membership interests in TML IV LLC (“ TML IV ”) for a purchase price of approximately $15.8 million.”

Marblegate Capital Corp entered into Receivables Loan and Security Agreement with the lenders from time to time party thereto, and DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, New York Branch, as agent valued at $120,000,000 (effective 2025-12-30).

“On December 30, 2025, subsidiaries of Marblegate Capital Corporation (“ MCC ”) entered into a Receivables Loan and Security Agreement (the “ Loan Agreement ”) by and among DePalma Financing SPV I LLC (the “ Borrower ”), DePalma Acquisition I LLC (“ DPA 1 ”), individually as servicer and as seller, the lenders from time to time party thereto (the “Lenders”), and DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, New York Branch, as agent (the “ Agent ”).”

MURPHY OIL CORP amended Second Amendment with JP Morgan Chase Bank, N.A. as administrative agent, and each of the lenders party thereto (effective 2026-01-02).

“On January 2, 2026, Murphy Oil Corporation (the “Company”) entered into an amendment (the “Second Amendment”) to its credit agreement dated October 7, 2024 (as previously amended, the “Credit Agreement”) with, among others, the Company, Murphy Exploration & Production Company – International and Murphy Oil Company Ltd. as borrowers, Murphy Exploration & Production Company and Murphy Exploration & Production Company – USA, as guarantors, JP Morgan Chase Bank, N.A. as administrative agent, and each of the lenders party thereto.”

STAAR SURGICAL CO terminated Agreement and Plan of Merger with Alcon Research, LLC (effective 2026-01-06).

“As previously disclosed, on August 4, 2025, STAAR Surgical Company (the “Company”) entered into an Agreement and Plan of Merger, dated as of August 4, 2025 (as amended, the “Merger Agreement”), by and among the Company, Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc.”

GERON CORP amended First Amendment to Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership valued at Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3 (effective 2026-01-05).

“On January 5, 2026, Geron Corporation ("we" or the "Company") entered into that certain first amendment to loan agreement (the "First Amendment Agreement") with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a "Lender"), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent (the "Agent"), which amends the terms of that certain Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement", and as amended by the First Amendment Agreement, the "Amended Loan Agreement), by and among the Company, the Lenders and the Agent.”